IP Library › Granted Patent US 7,459,449
Granted Patent B2
US 7,459,449 · App. 11/050,852 · Granted Dec 2, 2008

Stable salts of olanzapine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,459,449
App. No.
11/050,852
Granted
Dec 2, 2008
Kind
B2
Abstract

Several salts of olanzapine, including olanzapine malonate, olanzapine glycolate, olanzapine maleate, and olanzapine benzoate, have been found to have favorable solid state characteristics.

Claims (22)

1. A salt of olanzapine selected from the group consisting of olanzapine malonate, olanzapine glycolate, and olanzapine benzoate.

2. The salt according to claim 1 , which is olanzapine hydrogen malonate.

3. The salt according to claim 1 , which is olanzapine monoglycolate

4. The salt according to claim 1 , which is olanzapine monobenzoate.

5. The salt of olanzapine according to claim 1 , wherein said salt is crystalline.

6. The salt according to claim 5 , which is substantially free from an organic solvent.

7. A pharmaceutical composition comprising said salt according to claim 1 and at least one pharmaceutically acceptable excipient.

8. The composition according to claim 7 , wherein said composition is a solid form.

9. The composition according to claim 7 , wherein said composition is a liquid form.

10. The composition according to claim 9 , which further comprises an acid.

11. A method, which comprises administering an antipsychotic effective amount of the olanzapine salt according to claim 1 to a patient in need thereof.

12. The method according to claim 11 , wherein said effective amount of olanzapine salt is within the range of 0.25 to 30 mg, expressed in terms of the weight of the free base.

13. A process which comprises reacting olanzapine and a pharmaceutically acceptable acid selected from the group consisting of malonic acid, glycolic acid, and benzoic acid in a solvent to form a pharmaceutically acceptable acid addition salt of olanzapine.

14. The process according to claim 13 , which further comprises precipitating said salt of olanzapine from said solvent.

15. The process according to claim 14 , which further comprises isolating said salt of olanzapine as a solvent-free salt.

16. The process according to claim 15 , wherein said solvent is acetone.

17. The process according to claim 14 , which further comprises converting said acid addition salt olanzapine to form olanzapine free base.

18. The process according to claim 17 , which further comprises purifying said addition salt of olanzapine prior to said converting to olanzapine free base.

19. The pharmaceutical composition according to claim 7 , wherein said salt is olanzapine benzoate and said excipient comprises anhydrous dibasic calcium phosphate.

20. The pharmaceutical composition according to claim 19 , wherein said composition further comprises hydroxypropyl cellulose.

21. The pharmaceutical composition according to claim 19 , wherein said composition is an uncoated tablet.

22. The pharmaceutical composition according to claim 20 , wherein said composition is a tablet tat was made by direct compression.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2006
From: KELTJENS, ROLF
To: SYNTHON BV
Reel/Frame 018510/0395 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2006
From: SYNTHON BV
To: SYNTHON IP INC.
Reel/Frame 018510/0466 →
Continuity (3)
Provisional Application 6053912000 · Jan 27, 2004
Provisional Application 6056960700 · May 11, 2004
Related Publication 20050272721A1 · Dec 8, 2005